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Letter to the editor
Efﬁcacy  of  tigecycline,  polymyxin,  gentamicin,
meropenem and  associations  in experimental
Klebsiella pneumoniae  carbapenemase-producing
alKlebsiella pneumoniae  non-leth
Dear Editor,
Retrospective clinical data suggest that antibiotic combi-
nations,  including tigecycline (TIG) and polymyxin (POL),
result  in better outcomes than monotherapy against Klebsiella
pneumoniae carbapenemase (KPC)-producing K. pneumoniae
(KPC-KP).1 An in vitro study with time-kill assay has shown
that  TIG, POL and meropenem (MPN) as single agents do not
exhibit  efﬁcient bactericidal activity against most of the KPC-
producing  strains, and TIG alone might be a therapeutic option
for  infections caused by KPC-producers when bacteriostatic
activity is adequate, or combined with POL when bactericidal
activity is required. The TIG and MPN  association was  neither
synergistic  nor bactericidal against KPC-KP strains, suggesting
an  antagonist effect, as demonstrated by Pournasara et al. in
a previous publication in the IJAA.2 Additional in vivo tests are
warranted  to better assess killing kinetics of TIG in combina-
tion  with other antibiotics against KPC-producers.
After approval by the local Ethics Committee for Animal
Experimentation, a non-lethal experimental murine model
of  KPC-KP sepsis was  conducted, aiming to observe the
effect  of different monotherapies and antimicrobial combina-
tions  on blood cultures and quantitative peritoneal cultures.
Thirty-six rats were  inoculated with a low dose inoculum
(9  × 108 CFU/mL) of a KPC-KP. MPN  minimal inhibitory con-
centration (MIC) was  above 16 g/mL, but the strain was
susceptible to TIG (MIC = 1 g/mL), POL B (MIC < 0.5 g/mL) and
gentamicin  (MIC = 4 g/mL). Antibiotic dosages and combina-
tions  are described in Table 1. Dosages were  the same in
combined  and monotherapy groups. A control group without
antibiotic  was  included.
No  differences were  observed in untreated controls
and animals treated with MPN,  since both groups had
positive blood cultures and peritoneal ﬂuid cultures with
103–104 colony-forming units/mL (CFU/mL). All animals
treated with TIG, GEN and POL as monotherapy had negative
blood  cultures, as did the animals treated with POL plus sepsis
GEN,  POL plus TIG, TIG plus GEN and triple therapy. Those
groups  also presented negative peritoneal ﬂuid cultures,
except for two animals treated with TIG monotherapy, who
had  103 CFU/mL in peritoneal ﬂuid cultures. When POL and
TIG  were combined with MPN, three out of six blood cultures
turned  out positive after 12 h of incubation, a worse micro-
biological result than monotherapies with TIG, POL and GEN
and  other combinations.
All  monotherapies with TIG, POL and GEN (total n = 9)
showed higher efﬁcacy in sterilizing peritoneal and blood cul-
tures than the group of untreated controls and animals treated
with  MPN (n = 6) (p = 0.011). Triple therapy (MPN + TIG + POL)
and  double therapies with no MPN (TIG + POL, TIG + GEN,
POL  + GEN) (total n = 12) were signiﬁcantly more  effective than
controls  (untreated controls and animals treated with MPN
alone)  in sterilizing cultures (p = 0.011). On the other hand,
when  the TIG + MPN and POL + MPN  combinations (n = 6) were
compared  to untreated controls and animals receiving MPN
(n  = 6), there were  no signiﬁcant differences in culture posi-
tivity  (p = 0.275).
This ﬁnding must be conﬁrmed with larger samples, but
these  data suggest that combinations of MPN  with TIG or POL
might  have an antagonist effect in vivo.
As previously reported by Pournarasa, 2011, MPN  plus TIG
was  non-synergistic in this in vivo experiment. Additionally,
POL  plus MPN or TIG plus MPN associations may be less
effective than monotherapies or other combinations to treat
KPC-KP  sepsis.
Antibiotic associations should be cautiously used, even for
carbapenemase-producing Enterobacteriaceae strains. In vitro
studies showing this paradox or antagonist effects used empir-
ical  combination therapies in humans with infections by
KPC-KP.  An experimental study with concentrated inoculum
aiming  to evaluate the effect of antimicrobial combination in
lethal sepsis is ongoing and may  elucidate this subject. Clin-
ical  trials could answer those questions, but, until then, the
combined  therapy for synergistic effect of carbapenems and
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Table 1 – Experimental study with non-lethal sepsis in
rats  by KPC-producing Klebsiella pneumoniae.
Monotherapy was  compared with antibiotic
combinations. Meropenem combined with other
antibiotics besides having no beneﬁt, positive cultures
suggest an antagonistic effect.
Rats Positive blood
culture
>103 CFU/mL in
peritoneal ﬂuid
culture
No antibiotics 100% 100%
Meropenem 100% 100%
Gentamicin 0 0
Tigecycline 0  67%
Polymyxin B 0 0
Polymyxin B + tigecycline 0 0
Gentamicin + tigecycline 0 0
Polymyxin B + gentamicin 0 0
Gentamicin + meropenem 0 0
Polymyxin B + meropenem 67% 0
Tigecycline + meropenem 33% 0
Polymyxin
B + tigecycline + meropenem
0 0
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2CFU/mL, colony-forming units per milliliter.
ther classes of antimicrobials is not recommended, at least
or  strains with higher MPN  MIC.
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